Study of lymph node MRI (magnetic resonance imaging) agent completed:
This article was originally published in Clinica
Executive Summary
Advanced Magnetics has said it will file a new drug application with the FDA next year for its MRI contrast agent Combidex, following the completion of Phase III clinical trials. The Cambridge, Massachusetts-based company plans to market the agent for assisting in the diagnosis and staging of metastatic disease in lymph nodes as well as for detecting and characterising liver lesions.